These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

101 related articles for article (PubMed ID: 3617000)

  • 41. Drug-induced cancer.
    Prescrire Int; 2010 Feb; 19(105):21. PubMed ID: 20455337
    [No Abstract]   [Full Text] [Related]  

  • 42. [Postmarketing surveillance of drugs].
    Simon P; Soubrié C
    Rev Prat; 1983 Jan; 33(1-2):23-8. PubMed ID: 6823538
    [No Abstract]   [Full Text] [Related]  

  • 43. Postmarketing management of drug use: toward rational public policy.
    Spitzer WO; Hutchinson T; Lane D
    CMAJ; 1987 May; 136(10):1022-4. PubMed ID: 3567760
    [No Abstract]   [Full Text] [Related]  

  • 44. The effect of backgrounds in safety analysis: the impact of comparison cases on what you see.
    Gogolak VV
    Pharmacoepidemiol Drug Saf; 2003; 12(3):249-52. PubMed ID: 12733479
    [No Abstract]   [Full Text] [Related]  

  • 45. [Comprehensive detection of severe, potentially life-threatening drug side effects].
    Schönhöfer PS; Wessely-Stickel B; Schulte-Sasse H; Werner W
    Verh Dtsch Ges Inn Med; 1989; 95():687-90. PubMed ID: 2603504
    [No Abstract]   [Full Text] [Related]  

  • 46. [Organization and results of drug vigilance in France].
    Bégaud B; Chaslerie A; Haramburu F
    Rev Epidemiol Sante Publique; 1994; 42(5):416-23. PubMed ID: 7973001
    [TBL] [Abstract][Full Text] [Related]  

  • 47. [Forms of information supplied by regional drug monitoring centers. Assessment of the activity during 1984].
    Lavarenne J; Evreux JC
    Therapie; 1986; 41(5):323-6. PubMed ID: 3810517
    [No Abstract]   [Full Text] [Related]  

  • 48. ["There are clear criteria for product surveillance studies"].
    Throm S
    MMW Fortschr Med; 2009 Aug; 151(34-35):7. PubMed ID: 19771777
    [No Abstract]   [Full Text] [Related]  

  • 49. [Surveillance studies criticized. A marketing effort for expensive drugs? "Not throwing the baby out with the bath water" (interview by Dr. Beate Schumacher)].
    Selbmann HK
    MMW Fortschr Med; 2009 Aug; 151(34-35):6. PubMed ID: 19771776
    [No Abstract]   [Full Text] [Related]  

  • 50. Post marketing surveillance. Traps for the unwary.
    Marley J; Mant A
    Aust Fam Physician; 1993 Jun; 22(6):1009-11, 1013. PubMed ID: 8338446
    [TBL] [Abstract][Full Text] [Related]  

  • 51. [Methods for studying the adverse effects of drugs. I. Comparison of imputability methods: modelling and methodology].
    Péré JC; Begaud B; Haramburu F; Albin H
    Therapie; 1984; 39(3):279-89. PubMed ID: 6463953
    [No Abstract]   [Full Text] [Related]  

  • 52. Prescription for trouble: common drugs, hidden dangers. Tens of people are at risk.
    Consum Rep; 2006 Jan; 71(1):34-9. PubMed ID: 16491527
    [No Abstract]   [Full Text] [Related]  

  • 53. Pharmacovigilance in India: how safe are the new drugs? How sure are we?
    Joshi SR; Sapatnekar SM
    J Assoc Physicians India; 2008 Dec; 56():933-4. PubMed ID: 19322970
    [No Abstract]   [Full Text] [Related]  

  • 54. [How to report side-effects of drugs?].
    Guillaume JC
    Ann Dermatol Venereol; 1986; 113(4):375-6. PubMed ID: 3767239
    [No Abstract]   [Full Text] [Related]  

  • 55. [Evaluation of medication side-effects from an economic perspective].
    Segura O; Maldonado C
    Biomedica; 2003 Dec; 23(4):401-7. PubMed ID: 14968918
    [TBL] [Abstract][Full Text] [Related]  

  • 56. [Drug effects in elderly subjects: from the pharmacologic target to the risk-benefit. Round Table #5 of the 16th National Clinical Pharmacology Workshop].
    Lassale C; Piette F; Jolliet P
    Therapie; 2001; 56(4):363-7. PubMed ID: 11677853
    [TBL] [Abstract][Full Text] [Related]  

  • 57. Early postmarketing drug safety surveillance: data mining points to consider.
    Hauben M
    Ann Pharmacother; 2004 Oct; 38(10):1625-30. PubMed ID: 15304626
    [TBL] [Abstract][Full Text] [Related]  

  • 58. [Misuse of drugs: conclusions of the pharmacovigilance workshops at La Baule, France].
    Fermont I;
    Therapie; 2002; 57(3):283-8. PubMed ID: 12422543
    [TBL] [Abstract][Full Text] [Related]  

  • 59. Adverse drug reactions: a review of relevant factors.
    Ajayi FO; Sun H; Perry J
    J Clin Pharmacol; 2000 Oct; 40(10):1093-101. PubMed ID: 11028248
    [TBL] [Abstract][Full Text] [Related]  

  • 60. Should new drugs be avoided?
    Child Health Alert; 2002 Jun; 20():2. PubMed ID: 12096722
    [No Abstract]   [Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 6.